A meta-analysis of smoking status on clinical outcomes of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor.

Authors

Yoshikazu Hasegawa

Department of Medical Oncology, Izumi Municipal Hospital, Izumi, Osaka, Japan

Yoshikazu Hasegawa , Masahiko Ando , Makoto Maemondo , Satomi Yamamoto , Shun-ichi Isa , Hideo Saka , Akihito Kubo , Tomoya Kawaguchi , Minoru Takada , Takayasu Kurata , Sai-Hong Ignatius Ou

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major randomized trials.

First Author: Chee Lee

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).

First Author: Satoru Miura

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

EGFR Exon 20 insertion: Prognostic and predictive values in advanced non-small cell lung cancer, a real-world study.

First Author: Christos Chouaid

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

ctDNA levels before treatment predict survival in non-small cell lung cancer patients treated with a tyrosine kinase inhibitor.

First Author: Mariano Provencio-Pulla